News & Updates
Filter by Specialty:
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
The use of vedolizumab in the treatment of older patients with inflammatory bowel disease (IBD) appears to not only pose a higher risk of treatment failure but also offer no significant safety advantage when compared with tumour necrosis factor (TNF) antagonists, according to a study.
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
25 Oct 2022
Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases
Vonoprazan, a potassium competitive acid blocker (PCAB), is better than proton pump inhibitors (PPI) for the treatment of Helicobacter pylori and erosive oesophagitis, according to a new meta-analysis.
Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases
21 Oct 2022
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
19 Oct 2022
Sugar-sweetened drink intake tied to increased IBD risk
Consumption of sugar-sweetened beverages (SSBs) was associated with increased risk of inflammatory bowel disease (IBD), a large population-based study suggests. This association was not found with artificially sweetened beverages (ASBs) and natural juices.
